論文・技術情報追加のお知らせ

1. Association of Glucagon-Like Peptide-1 Receptor Agonists With Menstrual Events in Reproductive-Aged Patients.

GLP-1受容体作動薬と生殖年齢女性の月経異常の関連性調査。

対象DB：FAERS

2. Post-Marketing Ocular Adverse Events Associated with Tamoxifen and Raloxifene: A Population-Based Pharmacovigilance Study.

タモキシフェンとラロキシフェンの眼部副作用の比較評価。

対象DB：FAERS

3. Lorazepam during breastfeeding: a pharmacokinetic case report and exploratory pharmacovigilance assessment - a contribution from the ConcePTION project.

授乳期におけるロラゼパム使用の安全性と乳汁移行の評価。

対象DB：EudraVigilance,FAERS

4. Large Language Models for World Health Organization-Uppsala Monitoring Centre Drug-Adverse Event Causality Assessment Using Food and Drug Administration Adverse Event Reporting System Cases: Comparative Performance Study.

WHO-UMC因果関係評価における大規模言語モデルの性能評価。

対象DB：FAERS,KAERS

5. Adverse events associated with targeted therapy and immunotherapy for ovarian cancer: a FAERS pharmacovigilance study.

卵巣がんに対する分子標的薬・免疫療法の副作用の解析。

対象DB：FAERS

6. Pharmacovigilance analysis of severe cutaneous adverse reactions associated with antiseizure medications: a FAERS database study with time-to-onset evaluation.

抗てんかん薬による重症皮膚不良反応のシグナル検出と分析。

対象DB：FAERS

7. Evaluating the safety profile of poliomyelitis vaccines: insights from post-marketing surveillance.

ポリオワクチンの市販後安全性プロファイルの評価。

対象DB：FAERS,VAERS

8. Drug-induced paronychia: a disproportionality and time-to-onset pharmacovigilance study using FAERS and JADER.

FAERSを用いた薬剤性爪囲炎の副作用シグナルと発現時期解析。

対象DB：FAERS,JADER

9. Multi-method statistical signal aggregation with machine learning for severity classification of neonatal adverse drug reactions.

機械学習を用いた新生児の有害事象重症度分類とシグナル集計。

対象DB：FAERS

10. Postmarketing Safety Concerns With Caplacizumab: A Real-World Pharmacovigilance Study Based on the FDA Adverse Event Reporting System Database.

カプラシズマブの市販後安全性に関するリアルワールド解析。

対象DB：FAERS

11. Pharmacovigilance assessment of vinorelbine-associated adverse events using FAERS and VigiBase.

FAERSとVigiBaseを用いたビノレルビンの副作用評価。

対象DB：FAERS,VigiBase

12. Pharmacovigilance Analysis of Bleeding Events Associated With Selective Serotonin Reuptake Inhibitors (SSRIs) Using the US Food and Drug Administration Adverse Event Reporting System (FAERS).

SSRIおよびSNRI関連の出血リスクに関する副作用解析。

対象DB：FAERS

13. Real-world pharmacovigilance of drug-related bone metabolism disorders: integrating FAERS and VigiAccess with a Bradford Hill-based causal plausibility assessment.

薬剤性骨代謝異常のFAERSとVigiActivationを用いた解析。

対象DB：FAERS

14. Bone-related adverse events of hormonal therapy: A pharmacovigilance study based on the Food & Drug Administration Adverse Event Reporting System.

ホルモン療法による骨関連副作用のFAERSベースの調査。

対象DB：FAERS

15. Drug-associated lacrimal drainage obstruction: a population-based pharmacovigilance study.

薬剤に起因する涙道閉塞の人口ベースの市販後安全性調査。

対象DB：FAERS

16. Profiling Immune-Related Adverse Events Associated with Imatinib: A Two-Decade Real-World Safety Study Based on FDA Adverse Event Reporting System.

イマチニブによる免疫関連有害事象の20年間のリアルワールド分析。

対象DB：FAERS

17. Flibanserin safety in real-world use: a decade of US Food and Drug Administration Adverse Event Reporting System pharmacovigilance evidence.

フリバンセリンの市販後10年間の安全性データに基づく評価。

対象DB：FAERS

18. A real-world pharmacovigilance study of the FAERS database for fluvoxamine: perspectives from physicians and pharmacists.

FAERSデータベースを用いたフルボキサミンの副作用調査。

対象DB：FAERS

19. The onset of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) with the use of decongestant agents: a European pharmacovigilance analysis.

血管収縮症候群とPRESの発症時期に関するシグナル分析。

対象DB：EudraVigilance

20. Comparative Pharmacovigilance Analysis of Pulmonary Embolism Across Antipsychotics in VigiBase.

VigiBaseを用いた抗精神病薬間の肺塞栓症リスクの比較。

対象DB：VigiBase

21. Semiparametric Panel Count Model, With Applications to Signal Detection in Post-Market Drug Surveillance Systems.

市販後医薬品監視のシグナル検出における半パラメータモデル。

対象DB：VigiBase

22. Potential association of cluster headache with certain COVID-19 vaccines: An assessment from the pharmacovigilance databases.

新型コロナワクチンと群発頭痛の潜在的関連性の評価。

対象DB：FPVD,VigiBase

23. Altered mental status in cancer-related emergency hospitalizations: prevalence and recorded reasons for admission.

がん救急入院患者における精神状態変化の有病率と原因分析。

対象DB：DPC

24. Cerebrovascular disease and postoperative cognitive-related complications after knee arthroplasty: evidence from a nationwide cohort.

膝関節全置換術後の脳血管疾患と術後認知機能合併症の調査。

対象DB：DPC

25. Factors associated with non-steroidal anti-inflammatory drug continuation at discharge in patients with heart failure.

心不全入院患者の退院時NSAIDs継続に関連する要因分析。

対象DB：DPC

26. The Validation of the Effectiveness of Guidelines and the New Reimbursement Scheme for the Prevention of Secondary Hip Fractures in Japan - Current Status of Examination and Medication for Inpatients with Hip Fractures.

腎機能障害患者におけるガイドラインと新償還制度の検証。

対象DB：DPC

27. Epidemiology and treatment of patients with Essential Tremor: A retrospective cohort analysis in the United Kingdom.

ドイツにおける本態性振戦の疫学と治療に関するコホート分析。

対象DB：CPRD

28. Association between SARS-CoV-2 and diabetes: A population-based cohort study using the UK CPRD GOLD database.

SARS-CoV-2感染と糖尿病発症リスクの関連性に関する調査。

対象DB：CPRD

29. The prevalence and incidence of Raynaud's in England, United Kingdom.

英国イングランドにおけるレイノー病の有病率と罹患率の調査。

対象DB：CPRD

30. Migraine and risk of adverse obstetric outcomes: a matched cohort study of English linked electronic health records.

偏頭痛と産科的有害転帰リスクの関連性を示すコホート研究。

対象DB：CPRD

31. Evaluating Additional Roles in Primary Care: Expanding Capacity and Transforming Care Delivery.

プライマリケアにおける追加職種の役割拡大とケア提供の変革。

対象DB：CPRD

32. Menopause and musculoskeletal health in English primary care: study protocol.

英国プライマリケアにおける更年期障害と筋骨格系の健康計画。

対象DB：CPRD

33. Epidemiology, clinical management, and outcomes in patients with eosinophilic granulomatosis with polyangiitis in England: A retrospective observational cohort study.

好酸球性多発血管炎性肉芽腫症の疫学、臨床管理、転帰の調査。

対象DB：CPRD